TrialFrontiers in cellular and infection microbiology2021

Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.

Marthe Jøntvedt Jørgensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.